Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune signs deal with SBI Biotech

This article was originally published in Scrip

Executive Summary

MedImmunehas signed a licensing agreement with SBI Biotechto develop and commercialise the Japanese company's anti-ILT7 protein for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. SBI will receive an up-front payment as well as milestone payments and royalties on future marketed products. MedImmune has the rights to any resulting product candidates and will be responsible for preclinical and clinical development. It will also have the option to license additional targets resulting from SBI's research activities. Dave Mott, MedImmune's ex-CEO who left the company last July, has joined New Enterprise Associates, a venture capital firm active in the biotechnology field.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC025767

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel